{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:03:12Z","timestamp":1790733792316,"version":"4.1.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.549842","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T04:39:25Z","timestamp":1600922365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":135,"title":["Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring"],"prefix":"10.3389","volume":"11","author":[{"given":"Kathy","family":"Khoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Toutirais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Le Mauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy.","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron."},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/HAB-1997-8102","article-title":"Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis.","volume":"8","author":"Leger","year":"1997","journal-title":"Hum Antibodies."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis. (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2013unforeseen consequences.","volume":"353","author":"Berger","year":"2005","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience.","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing.","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis.","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis. (EAE). as a model for multiple sclerosis. (MS).","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.4049\/jimmunol.176.10.6225","article-title":"Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis.","volume":"176","author":"Kerfoot","year":"2006","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1172\/JCI11717","article-title":"Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.","volume":"107","author":"Theien","year":"2001","journal-title":"J Clin Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/1352458510392263","article-title":"CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.","volume":"17","author":"Frisullo","year":"2011","journal-title":"Mult Scler."},{"key":"B19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis.","volume":"59","author":"Niino","year":"2006","journal-title":"Ann Neurol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.4049\/jimmunol.155.6.2938","article-title":"Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4.","volume":"155","author":"Sato","year":"1995","journal-title":"J Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.4049\/jimmunol.1102515","article-title":"Cutting edge: loss of alpha4 integrin expression differentially affects the homing of Th1 and Th17 cells.","volume":"187","author":"Glatigny","year":"2011","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1084\/jem.20110434","article-title":"Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE.","volume":"208","author":"Rothhammer","year":"2011","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1177\/1352458514538111","article-title":"Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.","volume":"20","author":"Mancuso","year":"2014","journal-title":"Mult Scler."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081685","article-title":"Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.","volume":"8","author":"Mellergard","year":"2013","journal-title":"PLoS One."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/archneurol.2011.971","article-title":"Immunological markers of optimal response to natalizumab in multiple sclerosis.","volume":"69","author":"Villar","year":"2012","journal-title":"Arch Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult Scler."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1177\/1352458512463483","article-title":"Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.","volume":"19","author":"Harrer","year":"2013","journal-title":"Mult Scler."},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jneuroim.2015.08.010","article-title":"Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.","volume":"287","author":"Dallari","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1084\/jem.20140540","article-title":"VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.","volume":"211","author":"Schneider-Hohendorf","year":"2014","journal-title":"J Exp Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.","volume":"65","author":"del Pilar Martin","year":"2008","journal-title":"Arch Neurol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034103","article-title":"Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.","volume":"7","author":"de Andres","year":"2012","journal-title":"PLoS One."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0000000000001454","article-title":"Hematopoietic mobilization: potential biomarker of response to natalizumab in multiple sclerosis.","volume":"84","author":"Mattoscio","year":"2015","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/archneurol.2011.238","article-title":"Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.","volume":"68","author":"Saure","year":"2011","journal-title":"Arch Neurol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up.","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047578","article-title":"Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.","volume":"7","author":"Bornsen","year":"2012","journal-title":"PLoS One."},{"key":"B40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jaci.2016.11.045","article-title":"Recognition of viral and self-antigens by TH1 and TH1\/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses.","volume":"140","author":"Paroni","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.","volume":"141","author":"van Langelaar","year":"2018","journal-title":"Brain."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-95","article-title":"TH1\/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.","volume":"12","author":"Oreja-Guevara","year":"2012","journal-title":"BMC Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jneuroim.2017.06.012","article-title":"Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.","volume":"310","author":"Villani","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10875-011-9522-x","article-title":"Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.","volume":"31","author":"Ramos-Cejudo","year":"2011","journal-title":"J Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000210","article-title":"Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.","volume":"3","author":"Kimura","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003319","article-title":"Effects of natalizumab treatment on Foxp3+ T regulatory cells.","volume":"3","author":"Stenner","year":"2008","journal-title":"PLoS One."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1593-2","article-title":"Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.","volume":"16","author":"Traub","year":"2019","journal-title":"J Neuroinflammation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.","volume":"7","author":"Gonzalez-Suarez","year":"2017","journal-title":"Brain Behav."},{"key":"B51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML.","volume":"22","author":"Berger","year":"2016","journal-title":"J Neurovirol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) Project.","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol."},{"key":"B54","first-page":"179","article-title":"John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy.","volume":"41","author":"Pietropaolo","year":"2018","journal-title":"New Microbiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1182\/blood-2007-09-112052","article-title":"Increased numbers of circulating hematopoietic stem\/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.","volume":"111","author":"Bonig","year":"2008","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/bmt.2009.381","article-title":"CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.","volume":"45","author":"Jing","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"B57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1352458510385834","article-title":"CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.","volume":"17","author":"Warnke","year":"2011","journal-title":"Mult Scler."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.","volume":"111","author":"Zohren","year":"2008","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1128\/JVI.03221-13","article-title":"Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.","volume":"88","author":"Marshall","year":"2014","journal-title":"J Virol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab.","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.","volume":"68","author":"Rudick","year":"2010","journal-title":"Ann Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1086\/653823","article-title":"Human polyomavirus JC. (JCV). infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.","volume":"202","author":"Chapagain","year":"2010","journal-title":"J Infect Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.21443","article-title":"Detection of JC virus DNA fragments but not proteins in normal brain tissue.","volume":"64","author":"Perez-Liz","year":"2008","journal-title":"Ann Neurol."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development.","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/13550280802356837","article-title":"Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy.","volume":"14","author":"Marzocchetti","year":"2008","journal-title":"J Neurovirol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.24371","article-title":"Persistence and pathogenesis of the neurotropic polyomavirus JC.","volume":"77","author":"Wollebo","year":"2015","journal-title":"Ann Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/jmv.21805","article-title":"Natalizumab has no direct biological effect on JC virus infectivity in permissive human neural cell lines.","volume":"82","author":"Suzuki","year":"2010","journal-title":"J Med Virol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jns.2011.10.005","article-title":"CD49d expression as a promising biomarker to monitor natalizumab efficacy.","volume":"314","author":"Defer","year":"2012","journal-title":"J Neurol Sci."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.","volume":"13","author":"Sehr","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal Biochem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/cei.12590","article-title":"High interindividual variability in the CD4\/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.","volume":"180","author":"Harrer","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Mult Scler."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1177\/1352458518813657","article-title":"Therapeutic drug monitoring of natalizumab.","volume":"25","author":"Tanaka","year":"2019","journal-title":"Mult Scler."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/ene.13355","article-title":"John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.","volume":"24","author":"van Kempen","year":"2017","journal-title":"Eur J Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult Scler."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031784","article-title":"Lymphocyte subsets show different response patterns to in vivo bound natalizumab\u2013a flow cytometric study on patients with multiple sclerosis.","volume":"7","author":"Harrer","year":"2012","journal-title":"PLoS One."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/ane.12182","article-title":"Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?","volume":"129","author":"Wipfler","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B81","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clim.2016.08.003","article-title":"Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.","volume":"171","author":"Cobo-Calvo","year":"2016","journal-title":"Clin Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ana.25070","article-title":"To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.","volume":"82","author":"Scarpazza","year":"2017","journal-title":"Ann Neurol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2011.03.001","article-title":"Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.","volume":"234","author":"Harrer","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/cyto.b.21527","article-title":"Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients.","volume":"94","author":"Punet-Ortiz","year":"2018","journal-title":"Cytometry B Clin Cytom."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1177\/1352458512441688","article-title":"Prediction of antibody persistency from antibody titres to natalizumab.","volume":"18","author":"Jensen","year":"2012","journal-title":"Mult Scler."},{"key":"B87","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1177\/1352458512462920","article-title":"Characterization of anti-natalizumab antibodies in multiple sclerosis patients.","volume":"19","author":"Lundkvist","year":"2013","journal-title":"Mult Scler."},{"key":"B88","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1177\/1352458515604381","article-title":"Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.","volume":"22","author":"Signoriello","year":"2016","journal-title":"Mult Scler."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cellimm.2007.02.006","article-title":"Evolutionary deimmunization: an ancillary mechanism for self-tolerance?","volume":"244","author":"De Groot","year":"2006","journal-title":"Cell Immunol."},{"key":"B91","author":"Campbell","year":"2019","journal-title":"Evaluating the Efficacy and Safety of 6-Week Extended Interval Dosing of Natalizumab via a Prospective, Controlled, Randomized, Open-label, Rater-blinded Phase 3b Study. (NOVA)."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.549842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T03:10:23Z","timestamp":1696734623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.549842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2020.549842"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.549842","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"article-number":"549842"}}